Activities | Screening | Day 1 | Days 2–6 | Day 7 | Week 2 ± 1D | Week 3 ± 1D | Week 4 ± 1D | Week 8 ± 3D (treatment end) | Week 12 ± 3D4 | Week 24 ± 7D4 |
---|---|---|---|---|---|---|---|---|---|---|
Informed consent | √ |  |  |  |  |  |  |  |  |  |
History collection | Â | |||||||||
Inclusion/Exclusion | √ |  |  |  |  |  |  |  |  |  |
Concomitant medication1 |  | √ | √ | √ | √ | √ | √ | √ | √ | √ |
Physical examination | √ |  |  | √ | √ | √ | √ | √ | √ | √ |
Surgery conversion |  | √ | √ | √ | √ | √ | √ | √ | √ | √ |
Efficiency observation | Â | |||||||||
Neurological symptoms2 | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ |
Hematoma volume by CT2 | √ |  |  |  |  |  | √ | √ | √ | √ |
MGS-GCS/ADL-BI2 | √ |  |  | √ |  |  | √ | √ | √ | √ |
GOS |  |  |  |  |  |  | √ | √ | √ | √ |
Safety assessment | Â | |||||||||
Vital signs | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ |
Blood routine/Coagulation | √ |  |  |  |  |  | √ | √ | √ | √ |
Liver and renal function/Electrolyte/Lipids | √ |  |  |  |  |  | √ | √ | √ | √ |
Urinalysis | √ |  |  |  |  |  |  | √ |  | √ |
Electrocardiography | √ |  |  |  |  |  |  | √ |  | √ |
Pregnancy test | √ |  |  |  |  |  |  |  |  |  |
Adverse events |  | √ | √ | √ | √ | √ | √ | √ | √ | √ |
Others | Â | |||||||||
Drug dispensing | √ |  |  | √ | √ | √ | √ |  |  |  |
Drug recovery3 |  |  |  | √ | √ | √ | √ | √ |  |  |